Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer: An Open， Single-center Study

NCT05928312 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT05928312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05928312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer: An Open， Single-center Study
Lead sponsor
Zhejiang Cancer Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
August 28, 2023
Completion date
June 1, 2026
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer